GoodRx Q2 revenue $203.1M, Adj. EBITDA $69.4M; pharma segment up 32% YoY

GoodRx Holdings, Inc.

2025-Q2 EPS reported $0.06 revenue$406,040,000

Revenue $203.1M, net income $12.8M (6.3% margin); adjusted net income $33.9M (16.7% margin).
Adjusted EBITDA $69.4M (34.2% margin); operating cash flow $49.6M.
Pharma Manufacturer Solutions revenue +32% YoY; new pharmacy counter deals and ED subscription launched.
Results in line with prior guidance; no explicit revision to outlook provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.